Monitoring of phenobarbitone in epileptic children

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Epilepsy management in children requires careful drug level monitoring.
• Phenobarbitone is a common antiepileptic drug used in pediatric seizure disorders.
• Nutritional status can influence drug pharmacokinetics.

Purpose of the Study:

• To assess plasma phenobarbitone steady-state levels in children with varying nutritional status.
• To evaluate the therapeutic efficacy and toxicity of phenobarbitone in this population.
• To identify factors contributing to inter-individual variations in drug levels.

Main Methods:

• Monitored plasma steady-state levels of phenobarbitone in 75 children with seizure disorders.
• Assessed therapeutic efficacy and clinical toxicity.
• Correlated drug levels with nutritional status (including protein-energy malnutrition - PEM) and compliance.

Main Results:

• Significant inter-individual variation in phenobarbitone levels was observed.
• 10% had subtherapeutic levels, and 30% had potentially toxic levels (therapeutic range: 10-25 µg/ml).
• Higher levels were noted in children with Grade II PEM; poor compliance was a key factor. Therapeutic response correlated with drug levels in 60% of children.
• Clinical toxicity, primarily sedation and behavioral issues, occurred in two-thirds of patients.

Conclusions:

• Plasma phenobarbitone monitoring is essential for optimizing treatment in epileptic children.
• Nutritional status and patient compliance significantly impact phenobarbitone levels and therapeutic outcomes.
• Close monitoring can help prevent subtherapeutic levels, toxicity, and improve seizure control.